González M, Rojas N, Durán D, Schade A, Campos R, Milos C
Departamento de Bioquímica Clínica e Inmunología, Facultad de Farmacia, Universidad de Concepción, Chile.
Rev Med Chil. 1997 Aug;125(8):879-85.
Diabetes mellitus is a risk factor for atherosclerosis. Low density lipoproteins are considered a key factor in the formation of atheroma and the immune system has an important contribution to this process.
To quantify the immune response against modified low density lipoproteins in patients with non insulin dependent diabetes mellitus.
LDLs obtained from blood of healthy subjects, were glycated or altered with malondialdehyde and used as antigens. Serum autoantibodies against these LDLs were measured by ELISA in 22 patients with non insulin dependent diabetes mellitus aged 46 to 67 years old and 13 healthy controls aged 41 to 65 years old. Basal and LDL stimulated tumor necrosis factor a production in vitro, by peripheral leukocytes of diabetics and controls was also measured.
The ratio of glycated LDL/native LDL antibodies was higher in diabetics than in controls (9.37 +/- 2.72 and 0.41 +/- 0.11 respectively p < 0.05) and the ratio of MDA modified LDL/native LDL antibodies was not significantly different (8.64 +/- 3.83 and 2.14 +/- 1.26 respectively, NS). Tumor necrosis or production by leukocytes was higher in diabetics than in controls in basal conditions (53.3 +/- 15.3 and 26.9 +/- 14.7 arbitrary units (a.u.) respectively), when stimulated with native LDL (46.5 +/- 5 and 24.3 +/- 9.4 a.u. respectively), when stimulated with malondialdehyde modified LDL (50 +/- 16.2 and 24.4 +/- 7.7 a.u. respectively) or when stimulated with glycated LDL (38.3 +/- 8.8 and 14.4 +/- 7.5 a.u. respectively).
Diabetic patients have an enhanced immune response against low density lipoproteins, factor that could contribute to the accelerated atherogenesis of this disease.
糖尿病是动脉粥样硬化的一个危险因素。低密度脂蛋白被认为是动脉粥样硬化形成的关键因素，而免疫系统对这一过程有重要作用。
量化非胰岛素依赖型糖尿病患者针对修饰低密度脂蛋白的免疫反应。
从健康受试者血液中获取的低密度脂蛋白，经糖化或用丙二醛改变后用作抗原。采用酶联免疫吸附测定法（ELISA）检测了22例年龄在46至67岁的非胰岛素依赖型糖尿病患者和13例年龄在41至65岁的健康对照者血清中针对这些低密度脂蛋白的自身抗体。还检测了糖尿病患者和对照者外周血白细胞在体外基础状态下以及经低密度脂蛋白刺激后肿瘤坏死因子α的产生情况。
糖尿病患者糖化低密度脂蛋白/天然低密度脂蛋白抗体的比率高于对照组（分别为9.37±2.72和0.41±0.11，p<0.05），而丙二醛修饰低密度脂蛋白/天然低密度脂蛋白抗体的比率无显著差异（分别为8.64±3.83和2.14±1.26，无统计学意义）。在基础状态下，糖尿病患者白细胞的肿瘤坏死因子产生高于对照组（分别为53.3±15.3和26.9±14.7任意单位（a.u.）），经天然低密度脂蛋白刺激后（分别为46.5±5和24.3±9.4 a.u.），经丙二醛修饰低密度脂蛋白刺激后（分别为50±16.2和24.4±7.7 a.u.），或经糖化低密度脂蛋白刺激后（分别为38.3±8.8和14.4±7.5 a.u.）。
糖尿病患者对低密度脂蛋白的免疫反应增强，这一因素可能导致该疾病动脉粥样硬化加速。
